Marco Mielcarek, MD

Associate Member
Clinical Research Division
Associate Professor of Medicine
University of Washington

Research Interests

  • Preventing graft-versus-host disease (GVHD) after allogeneic stem cell transplantation:
    • clinical trials of donor or recipient statin treatment for GVHD-prevention
    • laboratory studies aimed at identifying mechanisms of statin-mediated immunosuppression
    • pre-clinical studies in the canine GVHD model
    • clinical trial of posttransplant cyclophosphamide for prevention of chronic GVHD after PBSC transplantation
  • Reducing the toxicity of GVHD treatment:
    • clinical trial of establishing safety and efficacy of low-dose glucocorticoids for treatment of acute GVHD
  • Establishing safety and efficacy of bortezomib maintenance therapy after allografting for patients with multiple myeloma

Clinical Expertise

  • Blood and bone marrow stem cell transplantation for hematologic cancers. Graft-versus-host disease (GVHD).

Current Studies

  • A Phase III Study to Determine Efficacy and Safety of Low-Dose Glucocorticoids for Initial Treatment of Acute Graft-versus-Host Disease (FH 2327)
  • A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation (FH 2541)
  • Tandem Autologous HCT / Nonmyeloablative Allogeneic HCT from HLA-Matched Related and Unrelated Donors Followed by Bortezomib Maintenance Therapy for Patients with High-Risk Multiple Myeloma (FH 2070)
  • Donor Statin Treatment for Prevention of Severe Acute GVHD after Myeloablative Hematopoietic Cell Transplantation (FH 2545)
  • Donor Statin Treatment for Prevention of Severe Acute GVHD after Nonmyeloablative Hematopoietic Cell Transplantation (FH 2546)


Contact Information

(206) 667-2827
(206) 667-6124
Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.